Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

1,013

Participants

Timeline

Start Date

August 19, 2010

Primary Completion Date

February 25, 2011

Study Completion Date

July 29, 2011

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal vaccine GSK 134612

One intramuscular injection

BIOLOGICAL

Menactra®

One intramuscular injection

Trial Locations (32)

13210

GSK Investigational Site, Syracuse

15106

GSK Investigational Site, Carnegie

16148

GSK Investigational Site, Hermitage

16501

GSK Investigational Site, Erie

16505

GSK Investigational Site, Erie

21045

GSK Investigational Site, Columbia

29651

GSK Investigational Site, Greer

29681

GSK Investigational Site, Simpsonville

30062

GSK Investigational Site, Marietta

30189

GSK Investigational Site, Woodstock

30281

GSK Investigational Site, Stockbridge

40356

GSK Investigational Site, Nicholasville

40509

GSK Investigational Site, Lexington

49127

GSK Investigational Site, Stevensville

63141

GSK Investigational Site, St Louis

67207

GSK Investigational Site, Wichita

78705

GSK Investigational Site, Austin

80501

GSK Investigational Site, Longmont

85224

GSK Investigational Site, Chandler

90723

GSK Investigational Site, Paramount

95405

GSK Investigational Site, Santa Rosa

95816

GSK Investigational Site, Sacramento

95823

GSK Investigational Site, Sacramento

97322

GSK Investigational Site, Albany

V3K 3P4

GSK Investigational Site, Coquitlam

V3R 8P8

GSK Investigational Site, Surrey

R3A 1M3

GSK Investigational Site, Winnipeg

A1A 3R5

GSK Investigational Site, St. John's

B3K 6R8

GSK Investigational Site, Halifax

L6T 3T1

GSK Investigational Site, Brampton

M9W 4L6

GSK Investigational Site, Toronto

N4S 5P5

GSK Investigational Site, Woodstock

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY